TP53-话题@MedSci

#TP53#

38篇内容 | 2827人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1458436, encodeId=635214584362b, content=<a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a>, objectTitle=Oncotarget：PARP1表达和TP53状态是区分胶质母细胞瘤亚型可靠标记物, objectType=article, longId=111113, objectId=6a2711111356, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a2711111356, replyNumber=0, likeNumber=79, createdTime=2017-08-30, rootId=0, userName=zblhy, userId=2d276073420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a2711111356, moduleTitle=Oncotarget：PARP1表达和TP53状态是区分胶质母细胞瘤亚型可靠标记物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a2711111356)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458435, encodeId=04b014584358d, content=<a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a>, objectTitle=Blood：携带TP53突变的套细胞淋巴瘤患者对现有疗法没有反应。, objectType=article, longId=109240, objectId=9dcd109240f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9dcd109240f3, replyNumber=0, likeNumber=109, createdTime=2017-08-20, rootId=0, userName=zblhy, userId=2d276073420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9dcd109240f3, moduleTitle=Blood：携带TP53突变的套细胞淋巴瘤患者对现有疗法没有反应。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9dcd109240f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458434, encodeId=f9db145843498, content=<a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a>, objectTitle=CLIN CANCER RES：肺癌TP53及KRAS突变预测阻断PD-1免疫治疗反应, objectType=article, longId=104354, objectId=cb2b10435459, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb2b10435459, replyNumber=0, likeNumber=74, createdTime=2017-07-04, rootId=0, userName=zblhy, userId=2d276073420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb2b10435459, moduleTitle=CLIN CANCER RES：肺癌TP53及KRAS突变预测阻断PD-1免疫治疗反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb2b10435459)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458433, encodeId=e90f1458433ae, content=<a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a>, objectTitle=Nature:干细胞移植需谨慎！TP53突变或使人癌上加癌, objectType=article, longId=97967, objectId=af9d9e9672e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af9d9e9672e, replyNumber=0, likeNumber=69, createdTime=2017-05-07, rootId=0, userName=zblhy, userId=2d276073420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af9d9e9672e, moduleTitle=Nature:干细胞移植需谨慎！TP53突变或使人癌上加癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af9d9e9672e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458432, encodeId=a23014584324b, content=<a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a>, objectTitle=Oncol Rep：首都医科大学贾继东等发现肝细胞癌的TP53突变与HCV阳性相关, objectType=article, longId=18503, objectId=80f018503d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80f018503d8, replyNumber=0, likeNumber=63, createdTime=2013-05-11, rootId=0, userName=zblhy, userId=2d276073420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80f018503d8, moduleTitle=Oncol Rep：首都医科大学贾继东等发现肝细胞癌的TP53突变与HCV阳性相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80f018503d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458431, encodeId=4a3c1458431dc, content=<a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a>, objectTitle=TP53缺失CLL更有效诱导方案, objectType=article, longId=5162, objectId=81215162a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81215162a7, replyNumber=0, likeNumber=72, createdTime=2012-04-15, rootId=0, userName=zblhy, userId=2d276073420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81215162a7, moduleTitle=TP53缺失CLL更有效诱导方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81215162a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TP53

2020-05-29

zblhy (审核中...)

前往app查看评论内容

#TP53#

Oncotarget：PARP1表达和TP53状态是区分胶质母细胞瘤亚型可靠标记物

2017-08-30

zblhy (审核中...)

前往app查看评论内容

#TP53#

Blood：携带TP53突变的套细胞淋巴瘤患者对现有疗法没有反应。

2017-08-20

zblhy (审核中...)

前往app查看评论内容

#TP53#

CLIN CANCER RES：肺癌TP53及KRAS突变预测阻断PD-1免疫治疗反应

2017-07-04

zblhy (审核中...)

前往app查看评论内容

#TP53#

Nature:干细胞移植需谨慎！TP53突变或使人癌上加癌

2017-05-07

zblhy (审核中...)

前往app查看评论内容

#TP53#

Oncol Rep：首都医科大学贾继东等发现肝细胞癌的TP53突变与HCV阳性相关

2013-05-11

zblhy (审核中...)

前往app查看评论内容

#TP53#

TP53缺失CLL更有效诱导方案

2012-04-15

科室
- - 订阅+
  - 更多科室
工具
服务